BTIG Sticks to Its Buy Rating for Zealand Pharma (ZLDPF)
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price ...
Wedbush Remains a Buy on BioMarin Pharmaceutical (BMRN)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...
What is Wedbush’s Estimate for Rezolute FY2029 Earnings?
Wedbush boosted their FY2029 earnings estimates for shares of Rezolute in a report released on Thursday, February 13th.
Q1 Earnings Forecast for Rezolute Issued By HC Wainwright
Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Rezolute in a research report issued on ...
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.
Rezolute's SWOT analysis: biotech stock advances on ersodetug trials
Rezolute , Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development of its lead drug candidate, ersodetug, for the treatment of congenital ...
Hosted on MSN6d
Rezolute’s Strategic Advances in Rare Disease Therapies
Rezolute, Inc. ( ($RZLT) ) has released its Q2 earnings. Here is a breakdown of the information Rezolute, Inc. presented to its investors.